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Cardiac remodeling and hypertrophy are the patho-
logical consequences of cardiovascular disease and
are correlated with its associated mortality. Activity of
the transcription factor NF-B is increased in the dis-
eased heart; however, our present understanding of
how the individual subunits contribute to cardiovas-
cular disease is limited. We assign a new role for the
c-Rel subunit as a stimulator of cardiac hypertrophy
and fibrosis. We discovered that c-Rel-deficient mice
have smaller hearts at birth, as well as during adult-
hood, and are protected from developing cardiac
hypertrophy and fibrosis after chronic angiotensin
infusion. Results of both gene expression and cross-
linked chromatin immunoprecipitation assay analy-
ses identified transcriptional activators of hypertro-
phy, myocyte enhancer family, Gata4, and Tbx
proteins as Rel gene targets. We suggest that the p50
subunit could limit the prohypertrophic actions of
c-Rel in the normal heart, because p50 overexpres-
sion in H9c2 cells repressed c-Rel levels and the ab-
sence of cardiac p50 was associated with increases in
both c-Rel levels and cardiac hypertrophy. We report
for the first time that c-Rel is highly expressed and
confined to the nuclei of diseased adult human hearts
but is restricted to the cytoplasm of normal cardiactissues. We conclude that c-Rel-dependent signaling is
critical for both cardiac remodeling and hypertrophy.
Targeting its activities could offer a novel therapeutic
strategy to limit the effects of cardiac disease. (Am J
Pathol 2012, 180:929–939; DOI: 10.1016/j.ajpath.2011.11.007)
Cardiovascular disease underpins the development of
cardiac hypertrophy and heart failure and is the primary
cause of death in the developed world.1 During periods
of acute physical and metabolic stress, the heart employs
hemodynamic coping mechanisms, including increasing
stroke volume and heart rate to meet the increased de-
mand. In response to prolonged stress, the heart under-
goes a physiological compensatory mechanism whereby
it becomes enlarged (ie, cardiac hypertrophy). This pro-
cess is governed by a series of biochemical and molec-
ular changes in the heart, including cardiac remodeling
and the reactivation of a group of genes collectively
known as the fetal gene program.2–4 Recent discoveries
in both animal models and the clinic suggest that cardiac
hypertrophy is a dynamic process that may be revers-
ible.5–7 Nonetheless, despite considerable research ef-
forts, the complex signaling events regulating develop-
ment and reversion of cardiac hypertrophy are not fully
understood.
Nuclear factor-B (NF-B) is a pleiotropic transcription
factor that, in addition to playing fundamental roles in
immunity, also regulates the expression of genes control-
ling cell survival and fate.8 NF-B activity is elevated
during cardiovascular disease, and its signaling is
strongly implicated in the development of cardiac remod-
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NF-B/Rel family comprises five members: RelA (p65),
NF-B1 (p105/p50), NF-B2 (p100/p52), c-Rel, and RelB.
These are divided into two classes. Class I subunits are
synthesized as precursors p105 and p100; these pro-
teins are then proteolytically processed, yielding the p50
and p52 subunits, respectively. The full-length proteins
contain ankyrin repeat domains and can act as inhibitory
B proteins. RelA (p65), c-Rel, and RelB proteins com-
prise the class II subunits. Importantly, only class II sub-
units contain a transactivation domain in the C-terminus
allowing them to interact with the transcriptional machin-
ery. The five subunits combine either as a homodimer or
as heterodimers that bind to a decameric DNA consen-
sus sequence known as the B site to modulate gene
transcription.8 NF-B is activated via two pathways, the
canonical (classical) and noncanonical pathway. Canon-
ical signaling uses the RelA, p50, and c-Rel subunits,
whereas activation of the noncanonical pathway is medi-
ated by RelB and p100/p52. Clinical studies have linked
canonical NF-B signaling with susceptibility and pro-
gression of cardiac disease, in that increased nuclear
RelA has been observed in failing human hearts,14,15
whereas NFKB1 gene polymorphisms are associated
with an increased susceptibility to developing dilated
cardiomyopathy.16,17
Global inhibition of this pathway using either pharma-
cological NF-B inhibitors, transgenic mice, or expres-
sion of dominant negative IB under the control of a
cardiac specific promoter in rodent models of heart dis-
ease is cardioprotective.18–21 These data highlight
NF-B as a potential therapeutic target. However, recent
data generated from studies using cardiac-specific
Nemo (or IKK), a regulatory subunit of NF-B,22 or IKK
knockout mice,23 the upstream kinases regulating canon-
ical NF-B signaling, revealed that activation of RelA is
critical for promoting myocyte survival and cardiac ho-
meostasis. This suggests that long-term pan-blockade of
IKK/RelA-dependent NF-B signaling in the diseased
heart is likely to be detrimental. However, NF-B biology
is complex, with multiple levels of control (including reg-
ulatory stimuli, activating kinases, post-translational mod-
ifications, and subunit composition).24–27 Each subunit is
functionally distinct and has discrete biochemical char-
acteristics. Growing evidence and knowledge now sug-
gest that the Rel subunit is important in study of NF-B
signaling in the context of disease.28–33 Given that the
RelA subunit is critical for cardiac homeostasis and there-
fore unlikely to be a good therapeutic target, we decided
to investigate the roles of the two other canonical NF-B
subunits, c-Rel and NF-B/p50, in cardiac disease.
These may provide more selective therapeutic targets,
leaving the cardioprotective actions of RelA signaling
intact.
In the present study, we began by comparing cardiac
expression of c-Rel in normal versus end-stage cardio-
myopathic human hearts. We show for the first time that
c-Rel was found in the nucleus of diseased but not nor-
mal hearts. We discovered that gene deletion of the c-Rel
subunit in mice protects against development of stress-
induced cardiac hypertrophy and fibrosis. Finally, wesuggest that the p50 subunit may act to antagonize the
prohypertrophic affects of c-Rel. With this report, we un-
ravel some of the complexities of NF-B system within
heart pathophysiology and identify a new role for the
c-Rel subunit as a positive regulator of cardiac hypertro-
phy. We suggest that the disease-related shift in balance
from p50 toward c-Rel-dependent signaling has a posi-
tive influence on the expression of genes controlling the
adaptive response of the stressed heart and that, unlike
RelA, the c-Rel subunit may prove to be a good thera-
peutic target for the treatment of cardiovascular disease.
Materials and Methods
Mice
Experiments were performed on either mixed C57Bl/6;
129PF2/J Nfkb1/ and F2 hybrid Nfkb1/ wild-type
(WT) control mice (Jackson Laboratory, Bar Harbor, ME)
or genetically modified mice lacking Nfkb1 or Rel on a
pure C57Bl/6 background and C57Bl/6 WT controls.34,35
Rel-deficient mice were a kind gift of Hsiou Chi-Liou (Weill
Cornell Medical College). Mice were housed in patho-
gen-free conditions. Age-matched, 12-week-old or new-
born (day 1) male Nfkb1/, Rel/, and WT control mice
were weighed, then euthanized by cervical dislocation;
the hearts were removed and weighed.
Blood Pressure Measurements
WT, Nfkb1/, and Rel/ mice were anesthetized by
intraperitoneal injection of a water solution with a fentanyl
and fluanisone combination (Hypnorm; VetaPharma,
Leeds, UK) and midazolam at the following doses, per
gram of body weight: 3.8 g fentanyl, 120 g fluanisone,
and 60 g midazolam. A 1.4-French Millar Mikro-Tip
pressure-volume catheter (ADInstruments, Oxford, UK)
was introduced into the right carotid artery and placed in
the ascending aorta. Systolic and diastolic pressures
were recorded using PowerLab Chart5 software and
analyzed using Millar PVAN data analysis software ver-
sion 3 (ADInstruments). Data are reported as means 
SEM of five mice per group.
Angiotensin Infusion
Age-matched adult WT or Rel/mice were anesthetized
with isoflurane, and Alzert 2004 mini-osmotic pumps (Du-
rect, Cupertino, CA) containing either 0.9% sterile saline
(vehicle) or angiotensin (700 g/kg per day) were placed
in the flank of the mouse. After 4 weeks of infusion, mice
were weighed, then euthanized by cervical dislocation;
the hearts were removed and weighed. All data are re-
ported as means  SEM of six WT and five Rel/ mice
per group.
Cell Culture
The rat embryonic cardiomyocyte cell line H9c2 (a kind
gift from Deborah Henderson, Newcastle, UK) was cul-
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supplemented with 100 units/mL penicillin, 100 g/mL
streptomycin, 2 mmol/L L-glutamine, and 10% fetal calf
serum, and was maintained at 37°C in an atmosphere of
5% CO2.
Human Left Ventricular Myocardium
Human left ventricular (LV) tissue was obtained frommale
patients undergoing cardiac transplantation for end-
stage heart failure. Normal nondonor suitable human LV
tissue was obtained from healthy male individuals in-
volved in road traffic accidents. Tissue was formalin-
fixed, processed, and embedded in paraffin blocks.
Histology, Immunohistochemistry, and Image
Analysis
Sirius Red and H&E staining was performed as described
previously.31 Photomicrographs were taken using a Leica
DMR and JVC camera system (Leica Microsystems, Wet-
zlar, Germany). Densitometry and cell areas were calcu-
lated using the Leica Qwin image analysis system in at
least six 20 fields in the left ventricle. Immunohisto-
chemical staining for mouse -sarcomeric actin, laminin,
and c-Rel was performed as follows. Slides were depar-
affinized, and then citric saline antigen retrieval was
performed. For c-Rel, a combination of citric saline and
trypsin antigen retrieval was performed. Endogenous
peroxidase activity was blocked using hydrogen perox-
ide, and further inhibition of nonspecific binding was
achieved using an avidin/biotin blocking kit (Vector Lab-
oratories, Peterborough, UK) followed by incubation with
20% swine serum (Dako, Ely, UK). Antibody specific to
-sarcomeric actin or laminin (Abcam, Cambridge, UK)
was diluted 1:250 in PBS and c-Rel (Santa Cruz Biotech-
nology, Santa Cruz, CA) diluted 1:50 in PBS with 20%
swine serum, then applied to the slides and incubated
overnight at 4°C. Slides were washed and amplification of
the antigen was achieved using a quick kit (Vector Lab-
oratories) for -sarcomeric actin or biotinylated swine
anti-rabbit diluted 1:200 (Dako), followed by ABC com-
plex (Vector Laboratories) for c-Rel and laminin. Slides
were then washed and presence of -sarcomeric actin,
laminin, or c-Rel was visualized with diaminobenzidine
staining. Slides were then counterstained with Mayer’s
hematoxylin, dehydrated, cleared in Clearene solvent
(Leica Microsystems), and mounted in Pertex mounting
medium (Leica Microsystems).
Total RNA Isolation and cDNA Synthesis
Total RNA was isolated from 10 to 15 g of heart tissue or
5  106 H9c2 cells using a total RNA purification kit
(Qiagen, Valencia, CA: Crawley, UK). Heart tissue was
homogenized using a sterile pestle in Qiagen RLT lysis
buffer, then 0.01% v/v proteinase K was added to the
homogenate, followed by incubation at 55°C for 10 min-
utes. RNA was then isolated according to the manufac-
turer’s instructions. RNA was treated with 1 L DNase(Promega, Madison, WI) for 30 minutes at 37°C and first-
strand cDNA was produced via incubation with random
hexamer primer [p(dN)6] and 100 units MMLV reverse
transcriptase, as described previously.31
SDS-PAGE and Immunoblotting
Murine heart tissue was lysed in Laemmli buffer, heated
at 95°C for 10 minutes, sonicated, and centrifuged for 30
minutes at 16,000  g. Total protein (10 to 30 g) was
fractionated by 9% SDS-PAGE and transferred to nitro-
cellulose. Blots were blocked with 0.1% TBS/Tween 20
containing 3% nonfat dried milk before overnight incuba-
tion with primary antibodies; c-Rel (rabbit, 1:1000; Santa
Cruz Biotechnology), -sarcomeric actin (mouse, 1:1000;
Abcam), p105/p50 (rabbit, 1:1000; Abcam), or GAPDH
(rabbit, 1:2000; Abcam). Membranes were washed in
TBS/Tween 20 and incubated with either mouse anti-
rabbit horseradish peroxidase conjugate (1:2000; Cell
Signaling Technology, Danvers, MA) or goat anti-rabbit
horseradish peroxidase conjugate (1:5000; Sigma-Al-
drich, St. Louis, MO) for 2 hours. Blots were washed
and antigen detected by enzymatic chemilumines-
cence (Amersham; GE Healthcare, Little Chalfont, UK).
SYBR Green Quantitative RT-PCR
Primers amplifying the mouse and rat target gene se-
quences of interest were designed using OLIGO software
version 4.0 (Molecular Biology Insights, Cascade, CO)
(Table 1). Gata4-specific primers were as described pre-
viously.36 Relative level of transcriptional difference be-
tween knockout and control mice was calculated as [1/(2A)]
100, where A is the difference between mean wild-type
CT andmean knockout CT after the GAPDH value has been
deducted from the target gene for each animal.
Plasmid DNA, Cell Transfection, and Reporter
Assays
Overexpression plasmids encoding respiratory syncytial
virus  galactosidase (RSV--gal), RSV-p50, and RSV-c-
Rel, described previously,37 were a gift from Neil D. Per-
kins (Newcastle University, UK). Transfection of H9c2
cells with 3 g of plasmid DNA was achieved using linear
polyethylenimine (m.w., 25,000; Polysciences, War-
rington, PA; Eppelheim, Germany) or Effectene (Qiagen)
reagent, as described previously.37,38 An 828-bp se-
quence from the Gata4 promoter was amplified from rat
genomic DNA using primers rat Gata4 PR Forward 5=-
TTAGCTAGCTCAAACTCCTCTAATCTCAGCAA-3= and
rat Gata4 PR Reverse 5=-AACGATATCTGAAGTTGGAT-
TACTGGAACAAT-3=. The forward primer contains a rec-
ognition site for NheI at the 5= end and the reverse primer
contains a cut site for EcoRV at the 3= end. The PCR
product was digested with NheI and EcoRV, purified, and
then cloned into an NheI-EcoRV digested pGL4.17 vector
(Promega) using T4 DNA ligase. The cloned promoter
sequence was then verified using sequencing. H9c2
cells were cotransfected with 1 g Gata4-luciferase and
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ng of Renilla (pRLTK) vector using an Effectene transfec-
tion kit (Qiagen). Cells were lysed in passive lysis buffer
48 hours after transfection, and luciferase and Renilla
activity was measured using a Stop & Glo kit (Promega).
Cross-Linked Chromatin Immunoprecipitation
Assay
A cross-linked chromatin immunoprecipitation (ChIP) as-
say was performed using 100 g cross-linked chromatin
prepared from H9c2 cells as described previously.38 In
each ChIP reaction, 10 g of antibody raised against
c-Rel (Santa Cruz Biotechnology), p50 (Abcam) or ap-
propriate irrelevant antibody control was used. The
3500-bp sequence upstream of ATG for each gene was
taken from the ENSEMBL database, and putative tran-
scription factor binding sites were predicted in silico using
Promo (available via the ALGGEN server, Polytechnic
University of Catalonia, Barcelona, Spain) Transfac 8.3
and TFSearch software (see Supplemental Table S1 at
http://ajp.amjpathol.org). ChIP primers for rat brain natri-
uretic peptide (BNP), rat atrial natriuretic peptide (ANP),
rat Gata4, rat Mef2A promoters, and Tgf1 exon 1-intron
1 boundaries were specific. The sequences were as fol-
lows. Rat BNP site 1 Forward 5=-CTATACAAGGCCT-
GCGGTTT-3= and reverse 5=-TGCCTCTGCTTTATCCTG-
3=; rat ANP forward 5=-GAGAGGAGCTGGACCATGAG-3=
and reverse 5=-CCCAGCATCCACATAAAAGC-3=; rat
Table 1. SYBR Green Quantitative RT-PCR Primers
Gene Forward prime
Rat/mouse Gapdh 5=-GCACAGTCAAGGCCGA
mouse RelA 5=-GCCCAGACCGCAGTAT
mouse RelB 5=-CTGGCTCCCTGAAGAA
mouse Rel 5=-CTCTGCCTCCCATTGT
mouse p52 5=-CTATCTGGTGATTGTG
mouse Mef 2A 5=-TACAAATCACACGCAT
mouse Mef 2B 5=-GCAACGCCTCTTCCAG
mouse Mef 2C 5=-ATGAGCGTAACAGACA
mouse Mef 2D 5=-ATGGGGAGGAAAAAGA
mouse Nkx2-5 5=-GCCAACAGCAACTTCG
mouse Tbx-5 5=-CTGGCCTTAATCCCAA
mouse Tbx-20 5=-GAGCAGCTCCTCAACA
mouse Foxm1b 5=-CCTGTCTCCTCCACTC
mouse ANP 5=-GCTCCTTCTCCATCAC
mouse BNP 5=-TATCTGTCACCGCTGG
rat Nkx2-5 5=-AGCGGCAGGACCAGAC
rat TBx5 5=-GGTCCGTAACTGGTAA
rat TBx20 5=-CAGATGGTGTCCTTTG
rat Mef 2A 5=-CAACATTAGCAGAGTC
rat Mef 2B 5=-AGGGGGACTGGGCACA
rat Mef 2C 5=-GCAGACGATTCAGTAG
rat Mef 2D 5=-TGTCCCCAAGTCGTGA
rat GATA4 5=-GCAGGGCGGAGGCAGT
rat ANP 5=-ACCTGGAGGAGAAGAT
rat BNP 5=-GTGCTGCCCCAGATGA
rat Rel 5=-TCGGTGTGTAAAGAAA
rat p50 5=-TGGTCACAAATGGAAA
rat RelB 5=-AGCGAAAGCGGGGACT
rat RelA 5=-TCACCAAAGACCCACC
rat p52 5=-ATGCGGAGAATGAAGA
The annealing temperature was 55°C for all primers.Mef2A forward 5=-TCTGCCCTGACATTCCCTAC-3= andreverse 5=-AGAGCTCCCAGGAACTACCC-3=; rat Gata4
sites 1 to 4 forward 5=-AGAGGGGCTTTTCGGTAGAA-3=
and reverse 5=-GAAAGTCCGAAGCAGTGTCC-3=; rat
Gata4 site 5 forward 5=-GTGCTCAGTCCTTCCTCTGG-3=
and reverse 5=-TGGAATACCACCCGGTAAGA-3=; and rat
Tgf1 exon 1-intron 1 forward 5=-GACCTGCTGGCA-
ATAGCTTC-3= and reverse 5=-ACGGGAGTGGGAGCA-
GAA-3=. The annealing temperature was 55°C. Primers
recognizing the PPAR exon 1-intron 1 boundaries have
been described previously.39 Each PCR reaction was
performed in triplicate, and the analysis was repeated in
at least three independent ChIP experiments. A signal
intensity value for each sample was calculated from the
mean of the experiments.
Statistical Analysis
P values were calculated using a two-tailed unpaired
Student’s t-test or one-way analysis of variance with
Tukey’s post hoc test or Bonferroni’s test for individual
subgroup comparison if required. In all tests, P  0.05
was used as the criterion for statistical significance.
Ethics
All animal experiments were approved by the local ethi-
cal review committee and were conducted under a
United Kingdom Home Office license. All human LV tis-
sue was collected by a protocol approved by the Pap-
Reverse primer
3= 5=-GCCTTCTCCATGGTGGTGAA-3=
5=-GTCCCGCACTGTCACCTG-3=
5=-CGCTCTCCTTGTTGATTC-3=
-3= 5=-GGCTTCCCAGTCATTCAACAC-3=
5=-GGCCGGTCCCTCATAGTT-3=
5=-GAAAATGATGAGTGCTAT-3=
5=-CAAGGAGCAGCGGGTAGG-3=
5=-TTGGTGCTGTTGAAGATG-3=
5=-GGAGTGGTTGAAGATGAT-3=
T-3= 5=-ACTCTGCACGGTGTTCAAGTCC-3=
-3= 5=-GCCAGTTACGGACCATTTGTATC-3=
-3= 5=-CCGTGGCTGGTACTTATGCATT-3=
= 5=-ACTGGGCTGAAATCTAACC-3=
3= 5=-ACCGGCATCTTCTCCTCCA-3=
3= 5=-TTGTGAGGCCTTGGTCCTTC-3=
5=-CGTAGGCGGGAGCGTAGG-3=
5=-ATTTTCGTCTGCTTTCAC-3=
5=-CCGTGTGGTCTTTCTTCT-3=
5=-TATTCGCACCAGTATTTC-3=
5=-GTGGTTAGGAAGGCGAAGC-3=
5=-CCTTTGTTTTCTTTCTTG-3=
5=-GCCGCATCCTCTTCACAG-3=
5=-AGGCGGTGGGGTGTAAGC-3=
3= 5=-TGTTGCAGCCTAGTCCGCTC-3=
5=-GGTCTATCTTCTGCCCAAAG-3=
5=-TCCATAGACTCGCTGACT-3=
5=-ATAGGCAAGGTCAGAATG-3=
5=-GATGGTGGGAGGAACAGG-3=
5=-AGGGGTTATTGTTGGTCT-3=
5=-GCATCCCCCAGTGACAGC-3=r
GAAT-
CC-3=
CC-3=
TTCTA
GA-3=
AA-3=
TA-3=
GG-3=
TT-3=
TGAAC
AACGA
GATGG
CTA-3
CCTG-
GAGG-
TC-3=
AG-3=
AA-3=
CA-3=
TC-3=
GT-3=
AC-3=
GG-3=
GCCG-
TT-3=
AA-3=
AA-3=
GC-3=
TC-3=
GC-3=worth (Cambridge) Hospital Tissue Bank review board
calculat
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(Reference: 06/Q0104/64). Written consent was obtained
from every individual according to the Papworth Tissue
Bank protocol.
Results
c-Rel Positively Regulates Cardiac Growth in
Mouse and Human
The canonical or classical NF-B signaling pathway uses
three of the five family members: RelA, c-Rel, and p50. Of
these, only RelA and c-Rel contain a transactivation do-
main.26 The p50 subunit lacks a transactivation domain,
and therefore p50 homo-dimers are unable to stimulate
gene transcription unless complexed with a coactiva-
tor.27,32 Previous studies have reported an increase in
RelA activation in the diseased heart,14,15 but studies
using genetically modified mice suggest that therapeutic
targeting of this subunit or its upstream kinases could be
detrimental, given that RelA signaling plays a vital role in
preventing cardiomyocyte apoptosis in response to car-
Figure 1. c-Rel regulates cardiac growth in mouse and human. A: Human LV
indicate nuclear staining; red arrows indicate cytoplasmic staining. Photom
cells were transiently transfected with RSV--gal (control plasmid) or RSV
expression of transcriptional activators of hypertrophy and hypertrophic ma
change  SEM, compared with RSV, of five independent transfections. C: Re
show decreased heart size in the knockout mice. Cardiac hypotrophy is furthe
with WT. Results are expressed as mean ratio change in Rel/ mice compar
mice, compared with controls. Photomicrographs show heart sections from
400. Scale bars: 100 m. Image analysis was used to calculate mean cytopla
WT  SEM; n  5 mice/group. E: Eight of the 10 genes measured were dow
fold change  SEM, relative to WT; n  5 mice/genotype. All P values were
t-test. *P  0.05, **P  0.01, and ***P  0.001.diac damage.22,23 However, the role of the other trans-activating subunit, c-Rel, in cardiac pathology has not
been characterized previously.
To ascertain whether c-Rel-dependent signaling plays
a role in the pathogenesis of cardiac disease, we per-
formed immunohistochemical staining for c-Rel in LV tis-
sue from normal and diseased human hearts (Figure 1A).
c-Rel was confined primarily to the nucleus in cardiomy-
ocytes in patients with end-stage ischemic or idiopathic
dilated cardiomyopathy. Conversely, in normal, nondis-
eased heart tissue we observed comparatively lower lev-
els of c-Rel, restricted to the cytoplasm. We hypothesize
that the nuclear localization of c-Rel in the diseased heart
alters the transcriptional activity of target genes and con-
tributes to disease pathogenesis. To identify candidate
prohypertrophic target genes under the control of c-Rel,
we overexpressed c-Rel in the neonatal rat cardiac cell
line H9c2. These experiments revealed that c-Rel induces
multiple genes that promote cardiac hypertrophy, including
transcriptional stimulators of hypertrophy (myocyte en-
hancer factor proteins Mef2A, Mef2C, and Mef2D, Gata4,
and Tbx5) and the cardioprotective factor BNP (Figure 1B).
Levels of Foxm1b, a transcription factor reported to regulate
lung and heart cell size and promote liver regeneration40,41
rom normal and diseased hearts was stained for c-Rel protein. Black arrows
hs are representative of five normal and five diseased human hearts. H9c2
B: Quantification of mRNA showed that c-Rel positively regulates cardiac
elative level of transcriptional difference RLTD was expressed as mean fold
ative images of hearts isolated from adult WT (left) and Rel/ mice (right)
hted by a decrease in heart/body weight ratio in mice lacking Rel, compared
WT  SEM; n  20 mice/group. D: Cardiomyocyte size is reduced in Rel/
Rel/ mice, stained with hematoxylin and eosin. Original magnification,
clear area ratios. Results are expressed as mean ratio change compared with
ated in Rel/ mice, compared with WT. Data are expressed as mean RLTD
ed using a one-way analysis of variance or an unpaired two-tailed Student’stissue f
icrograp
-c-Rel.
rkers. R
present
r highlig
ed with
WT and
smic/nu
n-regulwere also elevated when c-Rel was overexpressed. These
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would result in a reduction in heart size.
To test this idea, we isolated hearts from normal, non-
stressed adult Rel/ and WT mice. Rel-deficient mice
are viable and apparently normal, apart from some mod-
est immune defects, attenuated responses to liver injury,
and certain bacterial infections. We observed that the
Rel/ hearts appeared to be smaller than the WT con-
trols (Figure 1C). This was verified by a significant reduc-
tion in heart/body weight ratio in Rel knockout mice, com-
pared with WT controls. Blood pressure did not differ
significantly between Rel knockout and WT mice (see
Supplemental Table S2 at http://ajp.amjpathol.org), sug-
gesting that the cardiac phenotype is not a consequence
of hemodynamic changes. The reduction in overall heart
size and heart/body weight ratio was accompanied by a
decrease in the cytoplasmic/nuclear ratio of cardiomyo-
cytes in Rel-deficient hearts (Figure 1D). To determine
whether the reduction in heart size is a feature of devel-
opment or a postnatal phenotype, we measured the
heart/body weight ratio in newborn mice. This ratio was
also significantly reduced in Rel/ newborn mice, con-
firming that c-Rel can control cardiac growth during de-
velopment as well as in adult life (see Supplemental Fig-
ure S1A at http://ajp.amjpathol.org).
To determine whether c-Rel controls genes that regu-
late cardiomyocyte size, we next measured expression of
hypertrophy-associated genes in both genotypes. The
transcription factors Mef2A, Mef2C, Mef2D, Gata4, Tbx5,
and Tbx20 were expressed at reduced levels in Rel-
deficient heart (Figure 1E). Of note, all of these genes
were significantly up-regulated by overexpression of Rel
(Figure 1B). BNP was expressed at reduced levels in
Rel/ hearts (Figure 1E); by contrast, ANP levels were
elevated, which may indicate that a compensatory mech-
anism operates to ensure appropriate physiological lev-
els of this natriuretic peptide.
Gene Deletion of c-Rel Protects Against
Angiotensin-Induced Cardiac Hypertrophy
and Fibrosis
Our data show that c-Rel stimulates cardiac growth under
normal physiological conditions and that it is confined to
the nucleus in human diseased hearts. We therefore
asked whether c-Rel-dependent gene transcription is re-
quired for the development of cardiac hypertrophy. To
test this hypothesis, we subjected both Rel/ and WT
mice to 4 weeks of angiotensin or saline (vehicle) infusion
via a mini-osmotic pump. Prolonged exposure to angio-
tensin causes hypertension and chronic pressure over-
load, triggering cardiac remodeling, which in turn results
in cardiac hypertrophy and fibrosis. Calculation of heart/
body weight ratio confirmed the reduction in heart size in
saline-infused Rel/ mice, compared with the WT
(Figure 2A). Chronic angiotensin infusion caused a 27%
increase in heart/body weight ratio in WT mice. In Rel/
mice, however, the ratio was increased by 9%, only a
third of that observed in WT animals. This cardioprotec-
tive effect was further supported by a statistically signif-icant reduction in the cytoplasmic/nuclear area ratio of LV
cardiomyocytes in Rel/ mice, compared with WT mice,
treated with angiotensin, as shown by laminin immuno-
staining (Figure 2B; see also Supplemental Figure S1B at
http://ajp.amjpathol.org).
Cardiac remodeling and fibrosis are features of this
model. Morphometric analysis of Sirius Red staining for
collagen revealed that mice lacking Rel develop signifi-
cantly less fibrosis than control mice (Figure 2C). We also
noted a failure to up-regulate expression of key prohyper-
trophic transcription factors, including Mef2A and Nkx2-5,
and a suppression of basal Gata4 levels in chronic angio-
tensin-treated Rel/ mice. The inability to induce Mef2A
expression after angiotensin treatment in these mice is the
likely explanation for the observed increase in levels of the
cardioprotective peptide ANP; Naya et al42 reported that
ANP expression is elevated in Mef2A-deficient mice. Up-
regulation of ANP is a normal physiological response to
protect the heart from damage caused by pressure over-
load. Elevated expression of ANP could be another mecha-
nism conveying protection to Rel-deficient mice from chronic
angiotensin infusion-induced hypertrophy (Figure 2D).
c-Rel Directly Binds Hypertrophy-Related Gene
Promoters
To determine whether c-Rel directly regulates genes that
promote cardiac hypertrophy or whether the effects ob-
served in vitro and in vivo are indirect, we performed ChIP
assays. With this technique, we were able to demonstrate
a physical interaction between Rel and B regions of the
Gata4 (Figure 3A) and Mef2A (Figure 3B) gene promot-
ers, providing further evidence for c-Rel as a transcrip-
tional regulator of prohypertrophic genes. To determine
whether c-Rel or p50 can transactivate the Gata4 pro-
moter, we cotransfected H9c2 cells with a Gata4-lucifer-
ase construct and either RSV--gal, RSV-p50, or RSV-c-
Rel. Overexpression of c-Rel increased activity of the
Gata4-luciferase reporter construct by twofold, whereas
overexpression of p50 was without effect, suggesting that
c-Rel but not p50 is a critical transcriptional regulator of
the Gata4 gene (see Supplemental Figure S2A at http://
ajp.amjpathol.org).
To rule out nonspecific interaction of the c-Rel antibody
with the transcriptional machinery, we performed ChIP
analysis on the exon 1-intron 1 boundaries of Tgfb1 and
Pparg, two control genes that lack c-Rel binding sites. We
did not observe an interaction of p50 or c-Rel with either
gene, suggesting the interactions with Gata4, Mef2A, and
the natriuretic peptides are specific (Supplemental Fig-
ure S2B at http://ajp.amjpathol.org). This identifies c-Rel
but not p50 as the critical NF-B subunit regulating the
Mef2A promoter. These data are consistent with our ob-
servations in the angiotensin infusion model, in which Rel
gene-deficient mice fail to induce expression of Mef2A in
response to angiotensin. c-Rel was also recruited to the
gene promoters of the cardioprotective peptides ANP
and BNP (Figure 3C). These results verify that c-Rel not
only promotes transcription of hypertrophy-associated
genes but also directly binds their promoters.
ice/gen
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AJP March 2012, Vol. 180, No. 3The p50 Subunit of NF-B Represses c-Rel
Expression and Limits Cardiac Hypertrophy
and Fibrosis
Regulation of c-Rel at the transcriptional level is poorly
defined. To determine whether overexpression of either
p50 or c-Rel affects endogenous expression of the five
Figure 2. Rel knockout mice are protected from angiotensin-induced cardia
and WT mice after 4 weeks of saline vehicle or angiotensin (Ang) infusio
laminin-stained hearts. Data are expressed as mean percentage change, co
indicative of a hypertrophic response. By contrast, cardiomyocytes of angiote
effect. Representative photomicrographs show heart sections from angiotens
remodeling and fibrosis was reduced in angiotensin-infused Rel/ mice, com
analysis of Sirius Red-stained heart tissues showed a statistically significant i
collagen was observed in both the saline and angiotensin-infused Rel/ m
angiotensin-treated WT and Rel/ mice. Data are expressed as mean ratio o
mRNA levels of hypertrophy-associated genes were determined in Rel/
expression of transcriptional regulators of hypertrophy; however, this respon
mice and expressed as a mean fold change  SEM, relative to WT; n  4 m
 0.05, **P  0.01, and ***P  0.001.
Figure 3. c-Rel binds to hypertrophy-related gene promoters. Cross-linked
of hypertrophy (A and B) and to cardioprotective factors (C). In the promot
indicate preferential c-Rel consensus sequences, and purple boxes indicate
isolated and sheared by sonication, and 100 g of chromatin was incubate
Immunoprecipitation reactions were performed, proteins were digested, a
amplification of promoters of interest. Binding was normalized to total input genomic
three separate experiments. All P values were calculated using one way analysis ofNF-B subunits, we overexpressed p50 and c-Rel in
H9c2 cells and measured each family member at the
RNA level. Our data revealed that p50 can repress the
expression of c-Rel, whereas overexpression of c-Rel
leads to its own positive regulation (Figure 4A). These
data suggest that a function of p50 in the normal heart
may be to limit expression of c-Rel and limit its influence
rophy and fibrosis. A: The heart/body weight ratio was calculated in Rel/
ean cytoplasmic/nuclear area ratio was calculated using image analysis of
with WT. Cardiomyocyte size was increased in WT mice after angiotensin,
ated Rel/ mice were smaller than in the WT, suggesting a cardioprotective
d WT and Rel/ mice immunostained with anti-laminin antibodies. Cardiac
with WT. Original magnification, 400. Scale bars: 100 m. C: Densitometric
in collagen deposition in WT mice after angiotensin infusion; however, less
resentative photomicrographs show Sirius Red-stained heart sections from
tage change SEM; n 5 (Rel/) and n 6 (WT) mice/group. D: Relative
T mice after angiotensin infusion. Angiotensin infusion induces cardiac
tenuated in Rel/ mice. The RLTD was calculated between WT and Rel/
otype. All P values were calculated using a one-way analysis of variance. *P
alysis revealed binding of c-Rel to the promoters of transcriptional activators
atics, blue boxes indicate NF-B-c-Rel consensus sequences, yellow boxes
consensus sequences. H9c2 cells were formalin-fixed. Chromatin was then
n anti-c-Rel antibody, anti-p50 antibody, or irrelevant IgG isotype control.
s-links were reversed before purification of genomic DNA and qRT-PCRc hypert
n. B: M
mpared
nsin-tre
in-infuse
pared
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r percen
and W
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variance. *P  0.05, **P  0.01.
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compared NF-B subunit expression in the hearts of WT
and Nfkb1 (p50) knockout mice. Our data confirmed that
c-Rel is repressed by p50 (Figure 4B; see also Supple-
mental Figure S3A at http://ajp.amjpathol.org), given that
mice lacking this subunit have elevated cardiac levels of
c-Rel. We then predicted that hearts lacking p50 may be
enlarged, because the repressive effects of p50 have
been lost.
To test this idea, we isolated hearts from Nfkb1
(p50/) gene knockout and WT mice. Hearts from
Nfkb1/ mice were indeed larger than the WT con-
trols, as confirmed by heart/body weight ratios (Figure
4, C and D). This prohypertrophic phenotype was con-
served in two different mouse genetic backgrounds (Fig-
ure 4D; see also Supplemental Figure S3B at http://
ajp.amjpathol.org). Hypertrophy of Nfkb1/hearts was
confirmed by a statistically significant increase in the
number of sarcomeric units and cardiac sarcomeric actin
levels (Figure 5A; see also Supplemental Figure S3A at
http://ajp.amjpathol.org), as well as by an increase in the
cytoplasmic/nuclear ratio (Figure 5B; see also Supple-
mental Figure S3C at http://ajp.amjpathol.org). There was
no difference in blood pressure between the two geno-
types, suggesting that the spontaneous development of
cardiac hypertrophy in Nfkb1/ mice is not driven by
pre-load or after-load effects on the heart (see Supple-
mental Table S1 at http://ajp.amjpathol.org). For newborn
mice, however, we found no evidence of difference in
heart/body ratio, suggesting that hypertrophy develops
with adulthood (see Supplemental Figure S3D at http://
ajp.amjpathol.org).
Cardiac remodeling and fibrosis are common features
of heart damage and disease. Sirius Red staining re-
vealed spontaneous development of fibrosis in the hearts
of 12-week-old Nfkb1/ mice (Figure 5C). We next
sought to determine whether transcription factors that
drive cardiac hypertrophy are up-regulated in the hearts
Figure 4. p50 suppresses the prohypertrophic effects of c-Rel. H9c2 cells w
RSV-c-Rel). RNA was isolated, and cDNA was generated and used as a temp
SEM, relative to RSV, of five independent transfections. A: Gene expression le
expression of c-Rel. B: RNA was isolated from the hearts of adult WT and Nf
were quantified using qRT-PCR. c-Rel was the only NF-B subunit to be up-re
and expressed as a mean fold change  SEM relative to WT; n  5 mice/gen
adult WT and Nfkb1/ mice show increased heart size in Nfkb1/ mice. D
a pure C57Bl/6 background; data are expressed as mean percentage change
ratio was observed in male Nfkb1/ mice, compared with WT controls, inof Nfkb1/ mice. Levels of cardiac gene expression ofMef2 isoforms 2A, 2C and 2D were increased in Nfkb1/
mice, compared with controls, and all were down-regulated
in Rel-deficient mice. Gata4 is a key transcriptional regulator
linked to the development of cardiac hypertrophy, and its
expression was also elevated in these mice (Figure 5D).
We also observed an increased expression of Foxm1b in
Nfkb1/mice (Figure 5D), which may be highly relevant,
given the role previously suggested for this factor in or-
gan hypertrophy. Consistent with these data, markers of
cardiac hypertrophy Nkx2-5 and TBx20 were also ele-
vated in Nfkb1/ hearts.
The vasoactive hormones BNP and ANP are produced
by cardiomyocytes and are cardioprotective.43 BNP lev-
els were modestly elevated in Nfkb1/ heart; by contrast
expression of ANP was markedly suppressed. Of note,
genes for Mef2A, Gata4, and the natriuretic peptide BNP
were not only elevated in the Nfkb1/ hearts, but were
also identified as c-Rel target genes in the ChIP analysis.
Discussion
Activation of NF-B is strongly linked with the develop-
ment of cardiac growth and hypertrophy, and blockade
of this pathway has been proposed as a promising ap-
proach for prevention of adverse cardiac remodel-
ing.18–20 This idea is supported by clinical observations
and in rodent models of heart disease. Clinically, in-
creased nuclear translocation of the RelA subunit has
been observed in end-stage dilated cardiomyopathy.
Furthermore, Santos et al16 recently reported a polymor-
phism in the Nfkb1 gene that leads to reduced gene
activation, which is associated with an increase in onset
and progression of cardiac remodeling, cardiac deterio-
ration, and heart failure in patients with dilated cardiomy-
opathy. In rodent models of cardiac hypertrophy involv-
ing angiotensin II, isoproterenol, and aortic-banding,
significant cardioprotective effects were observed either
siently transfected with expression plasmids (control RSV--gal, RSV-p50, or
qRT-PCR. The RLTD was calculated and expressed as mean fold change 
the individual NF-B subunits revealed that overexpression of p50 repressed
mice, and mRNA levels of the NF-B subunits RelA, NF-B2, c-Rel, and RelB
in Nfkb1/mice. The RLTD between WT and Nfkb1/mice was calculated
*P  0.05, **P  0.01. C: Representative photographs of hearts isolated from
eart/body weight ratio was calculated in Nfkb1/ and WT control mice on
ompared with WT; n 17 mice/genotype. An increase in heart/body weight
ckgrounds. ***P  0.001.ere tran
late for
vels of
kb1/
gulated
otype.
: The hin mice expressing an NF-B super-repressor or in ro-
een WT
m.
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studies, however, have indicated that NF-B signaling is
cardioprotective in heart disease, particularly those
linked to the RelA subunit, because inhibiting the actions
of this subunit is likely to severely affect cardiomyocyte
homeostasis and survival.22,23,27,46 Hence, long-term
pan-blockade of NF-B signaling could be detrimental.
An alternative approach would be to target one or more of
the other four NF-B subunits. Here, we have described
for the first time a pivotal role for c-Rel as a stimulator of
cardiac hypertrophy and remodeling.
Our data suggest that c-Rel is predominantly found in
the cytoplasm of cardiomyocytes in the normal human
heart, whereas its localization is primarily nuclear in the
diseased human heart. Mice lacking c-Rel develop with
reduced heart size and are protected from angiotensin-
induced cardiac hypertrophy and fibrosis. We further
suggest that the p50 subunit limits the influence of c-Rel
on cardiac physiology by suppressing its expression.
The importance of this crosstalk between the two sub-
units was highlighted by our observation of spontaneous
development of cardiac hypertrophy and fibrosis in mice
lacking p50. Grumont et al47 identified three putative
NF-B binding sites in the Rel gene promoter. Their elec-
Figure 5. Features of cardiac hypertrophy and fibrosis are observed in Nfkb1
units were counted. The mean number (Ave) of sarcomeric units in Nfkb1/
photomicrographs of laminin-stained WT and Nfkb1/ mouse hearts. Mean
software. The ratio was significantly increased in Nfkb1/ hearts, compared
sections from WT and Nfkb1/ mice. Densitometric analysis revealed a stati
0.05. Data are expressed as means  SEM of eight WT and six Nfkb1/
hypertrophy myocyte enhancer factor 2 (Mef2) A, C, and D (but not Mef2B)
of Nfkb1 was associated with an increase in gene expression of Nkx2-5 an
peptide (BNP) and atrial natriuretic peptide (ANP) were quantified. BNP expr
of ANP was barely detectable in Nfkb1/ mice. RLTD was calculated betw
WT; n  5 mice/genotype. Original magnification, 400. Scale bars: 100 trophoretic mobility shift assay analysis revealed that Re-lA:p50 heterodimers and p50:p50 homodimers bind the
B1 and B3 sites; however, these sites exhibit a higher
affinity for the p50 homodimer, whereas dimers contain-
ing RelA, c-Rel, and p50 are bound to the B2 site.
Expression of c-Rel is regulated at the transcriptional
level in immune cells, and control of c-Rel has been
shown to vary greatly depending on stimulus, cell type
and cell function.48 Future investigation into the mecha-
nism by which p50 regulates c-Rel expression in the
normal and diseased heart is therefore warranted, given
that targeting the crosstalk between p50 and c-Rel may
reveal therapeutic opportunities.
Alternatively, the interaction of c-Rel with its target hy-
pertrophy-related genes (Mef2a and Gata4) may offer
strategies to inhibit cardiac remodeling. Activation of
Mef2A-dependent transcription is required for cardiac
development and growth and for initiating the phenotypic
reprogramming of myocytes that results in cardiac re-
modeling and hypertrophy2,42,49,50 Mef2A appears to be
a direct target of c-Rel, and therefore a plausible expla-
nation for the reduction in Rel knockout heart size at birth
and in adulthood could be insufficient production of
Mef2A (although this would require further investigation).
Furthermore, deficiency of c-Rel leads to a failure to in-
ut mice. A: Heart sections were stained for -sarcomeric actin and sarcomeric
as significantly increased, compared with WT. *P 0.05. B: Representative
yocyte cytoplasmic/nuclear area ratios were calculated using image analysis
. **P 0.01. C: Representative photomicrographs of Sirius Red-stained heart
ignificant increase in collagen deposition (red fibers) in Nfkb1/ mice. *P
ve, positive. D: Relative mRNA levels of the transcriptional regulators of
and Foxm1b were elevated in Nfkb1/ mice, compared with WT. Deletion
x20. Cardiac mRNA levels of the cardioprotective proteins brain natriuretic
as increased in the Nfkb1/mice, compared with WT; however, expression
and Nfkb1/ mice and expressed as mean fold change  SEM, relative toknocko
mice w
cardiom
with WT
stically s
mice.
, Gata4,
d of Tb
ession wduce Mef2A expression after chronic angiotensin infu-
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AJP March 2012, Vol. 180, No. 3sion, which was associated with protection from cardiac
fibrosis and enlargement. Mef2A expression was also
induced in cardiac cells overexpressing c-Rel and in
the hearts of mice lacking p50. Defining the nature of the
c-Rel-containing NF-B complexes assembled at the
promoters of Mef2a and other c-Rel target genes identi-
fied in the present study will be an important step toward
improving our understanding of the transcriptional mech-
anisms that regulate stress-induced remodeling of the
heart. Moreover, the regulatory events that lead to nu-
clear accumulation of c-Rel in the diseased human heart
will be of great interest and could be a potential source of
therapeutic targets.
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